quantisnow
FeedTopReportsPricing
⌘K
Live feed
16:19:54·1576d
INSIDERFiling
Dicerna Pharmaceuticals, Inc. logo

SEC Form 4: Fambrough Douglas returned $8,852,236 worth of shares to the company (231,431 units at $38.25), closing all direct ownership in the company

DRNA· Dicerna Pharmaceuticals, Inc.
Health Care
Original source

Companies

  • DRNA
    Dicerna Pharmaceuticals, Inc.
    Health Care

Recent analyst ratings

  • Dec 9UpdateChardan Capital$38.25
  • Nov 19UpdateRBC Capital$38.25
  • Nov 18UpdateHC Wainwright & Co.$38.25
  • Aug 11UpdateGoldman Sachs$25.00
  • Aug 10UpdateChardan Capital$28.00
  • Aug 10UpdateHC Wainwright & Co.$32.00

Related

  • PR576d
    Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Hardean Achneck, MD as Chief Medical Officer
  • SEC1564d
    SEC Form 15-12B filed by Dicerna Pharmaceuticals, Inc.
  • SEC1571d
    SEC Form EFFECT filed by Dicerna Pharmaceuticals, Inc.
  • SEC1571d
    SEC Form EFFECT filed by Dicerna Pharmaceuticals, Inc.
  • SEC1571d
    SEC Form EFFECT filed by Dicerna Pharmaceuticals, Inc.
  • SEC1571d
    SEC Form EFFECT filed by Dicerna Pharmaceuticals, Inc.
  • INSIDER1576d
    SEC Form 4: Koppel Adam closing all direct ownership in the company
  • INSIDER1576d
    SEC Form 4: Zeng Ling closing all direct ownership in the company
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022